Food and Drug Administration
Antiviral Drugs Advisory Committee
August 6, 2002
Briefing Information
NDA 21-449 Adefovir dipivoxil, for treatment of chronic hepatitis B (CHB) in adults
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Adefovir Dipivoxil For the Treatment of Chronic Hepatitis B, Gilead Sciences, Inc. pdf